摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

卡马西平 | 298-46-4

中文名称
卡马西平
中文别名
痛惊宁;卡巴咪嗪;立痛定;5H-二苯并[b,f]氮杂卓-5-甲酰胺
英文名称
carbamazepin
英文别名
carbamazepine;Cbz;5H-dibenzo[b,f]azepine-5-carboxamide;5H-dibenz[b,f]azepine-5-carboxamide;carbamezepine;5H-dibenz(b,f)azepine-5-caboxamide;benzo[b][1]benzazepine-11-carboxamide
卡马西平化学式
CAS
298-46-4
化学式
C15H12N2O
mdl
MFCD00005073
分子量
236.273
InChiKey
FFGPTBGBLSHEPO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    191-192 °C (lit.)
  • 沸点:
    378.73°C (rough estimate)
  • 密度:
    1.1099 (rough estimate)
  • 闪点:
    9℃
  • 溶解度:
    45% (w/v) aq 2-羟丙基-β-环糊精:可溶 29mg/mL
  • LogP:
    2.450
  • 物理描述:
    Solid
  • 颜色/状态:
    Crystals from absolute ethanol and benzene
  • 蒸汽压力:
    1.84X10-7 mm Hg at 25 °C (est)
  • 水溶性:
    -3.2
  • 稳定性/保质期:

    To study the photostability of carbamazepine polymorphs, the pure materials on the tablet surface were evaluated without physical damage by means of Fourier-transform infrared reflection-absorption infrared spectrometry (FT-IR-RAS) and colorimetric measurement of the carbamazepine polymorphs I, II, and III, after photodegradation at 2 irradiation intensities under a near-UV fluorescent lamp. The surface of sample pellets of all crystalline forms turned gradually from white to yellow-orange upon exposure to light, and the discoloration rate of form II was faster than that of forms I and III, indicating that form II was the most unstable of the three. The semilogarithmic plots of the photodegradation profiles of the various polymorphs were straight lines, including the induction period, indicating that degradation of the drug on the surface followed first-order kinetics. The induction periods of all forms were not significantly different. However, the degradation rate constant of form II was 5.1 and 1.5 times larger than those of forms I and III, respectively.

  • 解离常数:
    pKa = 13.9
  • 碰撞截面:
    150.3 Ų [M+H]+ [CCS Type: TW, Method: Major Mix IMS/Tof Calibration Kit (Waters)]
  • 保留指数:
    2296;2259;2259;2290;2285;2310;2337;2340;2280.2;2316.8;2275;2270;2290;2310;2290

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    18
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    46.3
  • 氢给体数:
    1
  • 氢受体数:
    1

ADMET

代谢
卡马西平主要在肝脏中代谢。CYP3A4肝酶是将卡马西平代谢为其活性代谢物卡马西平-10,11-环氧化物的主要酶,该环氧化物进一步通过环氧合酶酶转化为其反式二醇形式。其他参与卡马西平代谢的肝细胞色素酶包括CYP2C8、CYP3A5和CYP2B6。卡马西平还通过UGT2B7酶在肝脏中进行葡萄糖苷酸化,并发生其他几种代谢反应,形成次要的羟基代谢物和醌代谢物。有趣的是,卡马西平能诱导自身的代谢。这导致清除率增加,半衰期缩短,血清中卡马西平平降低。
Carbamazepine is largely metabolized in the liver. CYP3A4 hepatic enzyme is the major enzyme that metabolizes carbamazepine to its active metabolite, carbamazepine-10,11-epoxide, which is further metabolized to its trans-diol form by the enzyme epoxide hydrolase. Other hepatic cytochrome enzymes that contribute to the metabolism of carbamazepine are CYP2C8, CYP3A5, and CYP2B6. Carbamazepine also undergoes hepatic glucuronidation by UGT2B7 enzyme and several other metabolic reactions occur, resulting in the formation of minor hydroxy metabolites and quinone metabolites. Interestingly, carbamazepine induces its own metabolism. This leads to enhanced clearance, reduced half-life, and a reduction in serum levels of carbamazepine.
来源:DrugBank
代谢
单次口服卡马西平-10,11-环氧化物(100毫克)的药代动力学在10例长期单用拉莫三嗪(200-300毫克/天)治疗的患者和10例未用药的健康对照者中进行比较。在拉莫三嗪治疗的患者中,卡马西平-10,11-环氧化物的药代动力学参数与对照组相似(半衰期:7.2 ± 1.6 对比 6.1 ± 0.9小时;表观口服清除率:110.8 ± 53.1 对比 120.5 ± 29.9 ml/h/kg;表观分布容积:1.08 ± 0.37 对比 1.04 ± 0.25 l/kg,平均值 ± 标准差)。这些数据表明,与以前的建议相反,拉莫三嗪卡马西平-10,11-环氧化物的代谢处置没有影响。
The pharmacokinetics of a single oral dose of carbamazepine-10,11-epoxide, (100 mg) were compared in 10 patients on chronic monotherapy with lamotrigine, (200-300 mg/day) and in 10 drug-free healthy control subjects. Carbamazepine-10,11-epoxide pharmacokinetic parameters in lamotridge-treated patients were found to be similar to those observed in controls (half-life: 7.2 + or - 1.6 vs 6.1 + or - 0.9 hr; apparent oral clearance: 110.8 + or - 53.1 vs 120.5 + or - 29.9 ml/h/kg; apparent volume of distribution: 1.08 + or 0.37 vs 1.04 + or - 0.25 l/kg respectively; means + or - s.d.). These data indicate that, contrary to previous suggestions, lamotridge has no effect on the metabolic disposition of carbamazepine-10,11-epoxide.
来源:Hazardous Substances Data Bank (HSDB)
代谢
胎盘对卡马西平的转运和代谢在双循环胎盘叶状体灌注系统中进行了研究,并在16对母体静脉和脐血样本中进行了评估。 ... 添加到母体循环中的卡马西平安替比林更快地穿过胎盘,这与这些化合物的不同脂溶性相一致。由于安替比林卡马西平的转移率大约相同,卡马西平的转移机制可能类似于安替比林(被动扩散)。通过高效液相色谱或气相色谱/质谱未能在灌注液中检测到卡马西平的代谢物。通过改进的卡马西平代谢物的高效液相色谱方法,在临床样本中检测到六种代谢物,包括10-羟基-10,11-二氢卡马西平(10-OH-CBZ),之前仅在1例尿毒症患者中描述过。代谢物的相对平显示出显著个体差异。卡马西平迅速穿过灌注的胎盘,但这并不导致母体和胎儿循环中检测到的卡马西平代谢物。
Placental transfer and metabolism of carbamazepine was studied in a dual recirculating placental cotyledon perfusion system and was also evaluated in 16 pairs of maternal venous and cord blood samples. ... Carbamazepine added into the maternal circulation crosses the placenta in the beginning quicker than antipyrine which is in agreement with the different lipid solubilities of these compounds. Because the transfer rates of antipyrine and carbamazepine were about the same, the mechanism of transfer of carbamazepine is probably similar to that of antipyrine (passive diffusion). No metabolites of carbamazepine could be detected in the perfusate by high-performance liquid chromatography or gas chromatography/mass spectrometry. With the improved HPLC methodology for carbamazepine metabolites, six metabolites were detected in clinical samples, including 10-hydroxy-10,11-dihydro-carbamazepine (10-OH-CBZ), which has been described earlier in only 1 uremic patient. Relative levels of metabolites showed significant individual differences. Carbamazepine crosses perfused placenta rapidly, but this does not contribute to carbamazepine metabolites detected in maternal and fetal circulation.
来源:Hazardous Substances Data Bank (HSDB)
代谢
这项工作的目的是研究卡马西平在大鼠体内的血脑屏障转运、血液和肝脏的分布动力学、代谢相互作用以及局部肝脏代谢,使用微透析内部标准技术作为体内校准方法。卡马西平及其主要代谢物卡马西平-10,11-环氧化物在大鼠的海马和脑干中均匀分布。两者在大脑区域与血液区域下的浓度-时间曲线下面积之比与卡马西平的相比没有差异;对于卡马西平-10,11-环氧化物,海马的下面积为0.46 ± 0.08,脑干的下面积为0.45 ± 0.05。此外,在单次给予卡马西平后,研究了对照组动物和预先用氯米帕明处理的大鼠中卡马西平卡马西平-10,11-环氧化物在血液和肝脏中的处置情况。预处理组的卡马西平血液浓度曲线下面积增加了2倍,而卡马西平-10,11-环氧化物的血液浓度曲线下面积降低了33%,这表明氯米帕明抑制了卡马西平-10,11-环氧化物的形成。作为卡马西平-10,11-环氧化物形成的指标,卡马西平-10,11-环氧化物卡马西平浓度曲线下的面积之比在血液和肝脏中在对照组和氯米帕明预处理组之间没有差异,但是与对照动物相比,氯米帕明组的肝脏和血液中的比率显著降低。另外,卡马西平通过微透析探针局部给予肝脏的细胞外液。肝脏代谢比,即形成的卡马西平-10,11-环氧化物浓度与给予的卡马西平浓度的比值,范围从18.2 ± 1.2%到19.6 ± 1.6%。
The aim of this work was to study the transport across the blood-brain barrier, blood and liver distribution kinetics, metabolic interaction and local liver metabolism of carbamazepine in the rat, using microdialysis with the internal standard technique as in vivo calibration method. Carbamazepine and its major metabolite, carbamazepine-10,11-epoxide, are homogeneously distributed to hippocampus and cerebellum. The ratios of the areas under the concentration-time curve for both brain regions to blood areas under the concentration-time curve were not different from unity for carbamazepine; they were 0.46 + or - 0.08 (hippocampus) and 0.45 + or - 0.05 (cerebellum) for carbamazepine-10,11-epoxide. In addition, the disposition of carbamazepine and carbamazepine-10,11-epoxide in blood and liver, after a single dose of carbamazepine, was studied in control animals and in rats after pretreatment with clomipramine. A 2-fold increase in the blood areas under concentration curve of carbamazepine and a decrease to 33% of the blood areas under concentration curve of carbamazepine-10,11-epoxide in the pretreated group demonstrate the metabolic inhibition of carbamazepine-10,11-epoxide formation by clomipramine. The ratios of the areas under concentration curve carbamazepine-10,11-epoxide to the areas under the concentration curve carbamazepine, as a measure of carbamazepine-10,11-epoxide formation, were not different for blood and liver within the control and the clomipramine-pretreated groups, but the ratios were significantly lower for liver and blood in the clomipramine group compared with the control animals. In addition, carbamazepine was administered locally in the extracellular fluid of the liver via the microdialysis probe. The liver metabolic ratio, expressed as the ratio of the formed carbamazepine-10,11-epoxide concentration to the carbamazepine concentration administered, ranged from 18.2 + or - 1.2% to 19.6 + or - 1.6%.
来源:Hazardous Substances Data Bank (HSDB)
代谢
卡马西平已知的人类代谢物包括3-羟基卡马西平卡马西平10,11-环氧化物、2-羟基卡马西平和9-羟基卡马西平
Carbamazepine has known human metabolites that include 3-Hydroxycarbamazepine, Carbamazepine 10,11-epoxide, 2-Hydroxycarbamazepine, and 9-Hydroxycarbamazepine.
来源:NORMAN Suspect List Exchange
毒理性
  • 毒性总结
卡马西平通过阻断依赖性通道来抑制持续的重复放电。疼痛缓解被认为与三叉神经核中的突触传递阻断有关,而控制癫痫则与脊髓中突触传递的震后增强降低有关。卡马西平还具有抗胆碱能、中枢抗利尿、抗心律失常、肌肉松弛、抗抑郁(可能是通过阻断去甲肾上腺素的释放)、镇静和神经肌肉阻滞的特性。
Carbamazepine inhibits sustained repetitive firing by blocking use-dependent sodium channels. Pain relief is believed to be associated with blockade of synaptic transmission in the trigeminal nucleus and seizure control with reduction of post-tetanic potentiation of synaptic transmission in the spinal cord. Carbamazepine also possesses anticholinergic, central antidiuretic, antiarrhythmic, muscle relaxant, antidepressant (possibly through blockade of norepinephrine release), sedative, and neuromuscular-blocking properties.
来源:Toxin and Toxin Target Database (T3DB)
毒理性
  • 肝毒性
前瞻性研究表明,相当一部分服用卡马西平的患者会出现短暂的血清转酶升高(范围从1%到22%)。这些升高通常是良性的,不伴有肝脏组织学异常,即使在继续用药的情况下也会通常解决。此外,大多数服用卡马西平的患者会出现轻到中度的γ-谷酰转移酶(GGT)平升高,这可能是肝酶诱导而不是肝脏损伤的指标。显著转酶升高(超过5倍升高)的情况较少发生。 临床上明显的卡马西平肝毒性是不常见的但描述得很清楚,文献中报告了几百个病例。卡马西平肝毒性最常发生在抗惊厥药物超敏反应综合征的背景下,表现为发热,随后出现皮疹、面部肿、淋巴结病、白细胞计数升高和嗜酸性粒细胞增多或非典型淋巴细胞增多,开始治疗1到8周后(案例1和2)。这种综合征通常被称为药物皮疹伴嗜酸性粒细胞增多和系统性症状(DRESS)。DRESS综合征中最常见的系统性损害是肝脏损伤。肝脏损害范围从血清酶的轻度和暂时性升高到急性肝炎样综合征的突然发作,这种综合征可能很严重,甚至致命。然而,在卡马西平相关的DRESS综合征中,酶升高的最常见模式是混合性或胆汁淤积性损伤。肝脏活检显示胆汁淤积性损伤,伴有局灶性肝细胞坏死、嗜酸性粒细胞的突出和偶尔的肉芽肿。在致命的病例中,肝脏组织学还显示桥接、亚大块或大块坏死。卡马西平诱导的DRESS综合征的其他系统性损害包括肌炎、肾炎和肺炎。卡马西平诱导的DRESS综合征还与几例消失胆管综合征有关,这种综合征以严重的胆汁淤积性肝炎和免疫过敏性特征为特征,随后是持续的胆汁淤积,伴有瘙痒、黄疸和碱性磷酸平的显著升高。在大多数情况下,消失胆管综合征随时间逐渐改善,但有些情况很严重且不缓解,最终导致终末期肝病和死亡,或需要在发病几个月甚至几年后进行肝移植(案例3)。 卡马西平肝毒性也可以在没有免疫过敏性特征的情况下发生,在这种情况下,发病的潜伏期可以长达开始用药后6到12个月。没有免疫过敏性特征的卡马西平肝损伤病例倾向于是肝细胞性的而不是胆汁淤积性或混合性的,并且更可能是严重的(案例4)。卡马西平是急性肝衰竭案例系列中常见的药物。 可能性评分:A(已确立的临床上明显肝损伤的原因)。
Prospective studies indicate that a sizeable proportion of patients taking carbamazepine have transient serum aminotransferase elevations (ranging from 1% to 22%). These elevations are usually benign, not associated with liver histological abnormalities and usually resolve even with drug continuation. In addition, most patients on carbamazepine develop mild-to-moderate elevations in gamma glutamyltranspeptidase (GGT) levels, probably indicative of hepatic enzyme induction rather than liver injury. Marked aminotransferase elevations (more than 5 fold elevated) occur less frequently. Clinically apparent hepatotoxicity from carbamazepine is uncommon but well described, there being several hundred cases reported in the literature. Carbamazepine hepatotoxicity most often occurs in the setting of anticonvulsant hypersensitivity syndrome with onset of fever, followed by rash, facial edema, lymphadenopathy, elevations in white count and eosinophilia or atypical lymphocytosis, 1 to 8 weeks after starting therapy (Case 1 and 2). This syndrome is usually referred to as Drug Rash with Eosinophilia and Systemic Symptoms [DRESS]. The most frequent form of systemic involvement in DRESS syndrome is liver injury. The liver involvement ranges from mild and transient elevations in serum enzymes to abrupt onset of an acute hepatitis-like syndrome that can be severe and even fatal. However, the most common pattern of enzyme elevations in carbamazepine related DRESS syndrome is a mixed or cholestatic injury. Liver biopsy shows the cholestatic injury with focal hepatocellular necrosis, prominence of eosinophils and occasionally granulomas. In fatal cases, liver histology also shows bridging, submassive or massive necrosis. Other systemic involvement in carbamazepine induced DRESS syndrome includes myositis, nephritis and pneumonitis. Carbamazepine induced DRESS syndrome has also been linked to several cases of vanishing bile duct syndrome in which a severe cholestatic hepatitis with immunoallergic features is followed by persistence of cholestasis with itching, jaundice and prominent elevations in alkaline phosphatase levels. In most instances, vanishing bile duct syndrome gradually improves with time, but some instances are severe and unremitting, leading eventually to end stage liver disease and death or need for liver transplantation several months or even years fter onset (Case 3). Carbamazepine hepatotoxicity can also occur without immunoallergic features in which case the latency to onset can be as long as 6 to 12 months after starting. The cases of carbamazepine liver injury without immunoallergic features tend to be hepatocellular rather than cholestatic or mixed and are more likely to be severe (Case 4). Carbamazepine is a commonly listed agent in case series of acute liver failure. Likelihood score: A (Well established cause of clinically apparent liver injury).
来源:LiverTox
毒理性
  • 药物性肝损伤
药物:卡马西平
Compound:carbamazepine
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
毒理性
  • 药物性肝损伤
药物性肝损伤标注:最令人关注的药物性肝损伤
DILI Annotation:Most-DILI-Concern
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
毒理性
  • 药物性肝损伤
严重程度等级:7
Severity Grade:7
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
吸收、分配和排泄
  • 吸收
卡马西平生物利用度在摄入剂量的75-85%之间。在一项药代动力学研究中,一次服用200毫克口服缓释卡马西平后,测得的卡马西平Cmax为1.9 ± 0.3微克/毫升。Tmax为19 ± 7小时。在每隔12小时服用800毫克的几个剂量后,测得的卡马西平峰值浓度为11.0 ± 2.5微克/毫升。Tmax降至5.9 ± 1.8小时。缓释卡马西平在200-800毫克范围内表现出线性药代动力学。**食物对吸收的影响**高脂肪含量的餐食增加了400毫克剂量的吸收速度,但并未改变卡马西平的AUC。在饱食和空腹状态下,消除半衰期保持不变。缓释卡马西平的药代动力学在空腹状态下或与食物同服时相似。根据这些发现,食物摄入对卡马西平吸收的影响不大。
The bioavailability of carbamazepine is in the range of 75-85% of an ingested dose. After one 200 mg oral extended-release dose of carbamazepine in a pharmacokinetic study, the Cmax carbamazepine was measured to be 1.9 ± 0.3 mcg/mL. The Tmax was 19 ± 7 hours. After several doses of 800 mg every 12 hours, the peak concentrations of carbamazepine were measured to be 11.0 ± 2.5 mcg/mL. The Tmax was reduced to 5.9 ± 1.8 hours. Extended-release carbamazepine demonstrated linear pharmacokinetics over a range of 200–800 mg. **Effect of food on absorption** A meal containing high-fat content increased the rate of absorption of one 400 mg dose but not the AUC of carbamazepine. The elimination half-life remained unchanged between fed and fasting state. The pharmacokinetics of an extended-release carbamazepine dose was demonstrated to be similar when administered in the fasted state or with food. Based on these findings, food intake is unlikely to exert significant effects on carbamazepine absorption.
来源:DrugBank
吸收、分配和排泄
  • 消除途径
口服放射性碳酰胺咪嗪后,检测到72%的给药放射性剂量出现在尿液中,其余摄入剂量在粪便中找到。碳酰胺咪嗪主要以羟基化和结合代谢物的形式排出,仅有极少量未改变的药物。
After an oral dose of radiolabeled carbamazepine, 72% of the administered radioactive dose was detected in the urine and the remainder of the ingested dose was found in the feces. Carbamazepine is mainly excreted as hydroxylated and conjugated metabolites, and minimal amounts of unchanged drug.
来源:DrugBank
吸收、分配和排泄
  • 分布容积
在一项药代动力学研究中发现,卡马西平的分布体积为1.0升/公斤。另一项研究表明,卡马西平的分布体积介于0.7到1.4升/公斤之间。卡马西平能穿过胎盘,与肺和脑组织相比,这种药物在肝脏和肾脏中的浓度更高。卡马西平通过血脑屏障的情况各不相同。
The volume of distribution of carbamazepine was found to be 1.0 L/kg in one pharmacokinetic study. Another study indicates that the volume of distribution of carbamazepine ranges between 0.7 to 1.4 L/kg.. Carbamazepine crosses the placenta, and higher concentrations of this drug are found in the liver and kidney as opposed to lung and brain tissue. Carbamazepine crosses variably through the blood-brain barrier.
来源:DrugBank
吸收、分配和排泄
  • 清除
在一项药代动力学研究中,卡马西平在一次给药后的表观口服清除率为25 ± 5 mL/min,而在多次给药后为80 ± 30 mL/min。
In a pharmacokinetic study, the apparent oral clearance of carbamazepine was 25 ± 5 mL/min after one dose of carbamazepine and 80 ± 30 mL/min after several doses.
来源:DrugBank
吸收、分配和排泄
吸收:缓慢且不定,但几乎完全通过胃肠道吸收。
Absorption: Slow and variable, but almost completely absorbed from gastrointestinal tract.
来源:Hazardous Substances Data Bank (HSDB)

安全信息

  • 危险品标志:
    Xn
  • 安全说明:
    S22,S24,S36/37/39,S37
  • 危险类别码:
    R22,R42/43
  • WGK Germany:
    2
  • 海关编码:
    2933990090
  • 危险品运输编号:
    3249
  • 危险类别:
    6.1(b)
  • RTECS号:
    HN8225000
  • 包装等级:
    III
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335,H351,H361
  • 储存条件:
    2-8℃储存。

SDS

SDS:07cd6124a60f8ed451aaaace9b9776c9
查看
卡马西平 修改号码:5

模块 1. 化学
产品名称: Carbamazepin
修改号码: 5

模块 2. 危险性概述
GHS分类
物理性危害 未分类
健康危害
急性毒性(经口) 第4级
特异性靶器官毒性 血液
- 单一接触 [第2级]
环境危害 未分类
GHS标签元素
图标或危害标志
信号词 警告
危险描述 吞咽有害。
可能因延长或接触对器官产生损害: 血液
防范说明
[预防] 切勿吸入。
使用本产品时切勿吃东西,喝或吸烟。
处理后要彻底清洗双手。
[急救措施] 食入:若感不适,呼叫解毒中心/医生。漱口。
若感不适:求医/就诊。
[废弃处置] 根据当地政府规定把物品/容器交与工业废弃处理机构。

模块 3. 成分/组成信息
单一物质/混和物 单一物质
化学名(中文名): 卡马西平
百分比: >97.0%(N)
CAS编码: 298-46-4
俗名: 5H-Dibenzo[b,f]azepine-5-carboxamide
卡马西平 修改号码:5

模块 3. 成分/组成信息
分子式: C15H12N2O

模块 4. 急救措施
吸入: 将受害者移到新鲜空气处,保持呼吸通畅,休息。若感不适请求医/就诊。
皮肤接触: 立即去除/脱掉所有被污染的衣物。用大量肥皂和轻轻洗。
若皮肤刺激或发生皮疹:求医/就诊。
眼睛接触: 用小心清洗几分钟。如果方便,易操作,摘除隐形眼镜。继续清洗。
如果眼睛刺激:求医/就诊。
食入: 若感不适,呼叫解毒中心/医生。漱口。
紧急救助者的防护: 救援者需要穿戴个人防护用品,比如橡胶手套和气密性护目镜。

模块 5. 消防措施
合适的灭火剂: 干粉,泡沫,雾状二氧化碳
特殊危险性: 小心,燃烧或高温下可能分解产生毒烟。
特定方法: 从上风处灭火,根据周围环境选择合适的灭火方法。
非相关人员应该撤离至安全地方。
周围一旦着火:如果安全,移去可移动容器。
消防员的特殊防护用具: 灭火时,一定要穿戴个人防护用品。

模块 6. 泄漏应急处理
个人防护措施,防护用具, 使用个人防护用品。远离溢出物/泄露处并处在上风处。
紧急措施: 泄露区应该用安全带等圈起来,控制非相关人员进入。
环保措施: 防止进入下道。
控制和清洗的方法和材料: 清扫收集粉尘,封入密闭容器。注意切勿分散。附着物或收集物应该立即根据合适的
法律法规处置。

模块 7. 操作处置与储存
处理
技术措施: 在通风良好处进行处理。穿戴合适的防护用具。防止粉尘扩散。处理后彻底清洗双手
和脸。
注意事项: 如果粉尘或浮质产生,使用局部排气。
操作处置注意事项: 避免接触皮肤、眼睛和衣物。
贮存
储存条件: 保持容器密闭。存放于凉爽、阴暗处。
远离不相容的材料比如氧化剂存放。
包装材料: 依据法律。

模块 8. 接触控制和个体防护
工程控制: 尽可能安装封闭体系或局部排风系统,操作人员切勿直接接触。同时安装淋浴器和洗
眼器。
个人防护用品
呼吸系统防护: 防尘面具。依据当地和政府法规。
手部防护: 防护手套。
眼睛防护: 安全防护镜。如果情况需要,佩戴面具。
皮肤和身体防护: 防护服。如果情况需要,穿戴防护靴。

模块 9. 理化特性
外形(20°C): 固体
外观: 晶体-粉末
卡马西平 修改号码:5

模块 9. 理化特性
颜色: 白色类白色
气味: 无资料
pH: 无数据资料
熔点:
191°C
沸点/沸程 无资料
闪点: 无资料
爆炸特性
爆炸下限: 无资料
爆炸上限: 无资料
密度: 无资料
溶解度:
[] 不溶于
[其他溶剂]
溶于: 甲醇, 丙酮, 氯仿, 二甲基甲酰胺, 丙二醇, 乙二醇乙醚
微溶于: 乙醇, 冰乙酸
log分配系数 = 1.98

模块 10. 稳定性和反应性
化学稳定性: 一般情况下稳定。
危险反应的可能性: 未报道特殊反应性。
须避免接触的物质 氧化剂
危险的分解产物: 一氧化碳, 二氧化碳, 氮氧化物 (NOx)

模块 11. 毒理学信息
急性毒性: orl-rat LD50:1957 mg/kg
orl-wmn LDLo:1920 mg/kg/17W-I
ipr-rat LD50:158 mg/kg
对皮肤腐蚀或刺激: 无资料
对眼睛严重损害或刺激: 无资料
生殖细胞变异原性: 无资料
致癌性:
IARC = 无资料
NTP = 无资料
生殖毒性: 无资料
RTECS 号码: HN8225000

模块 12. 生态学信息
生态毒性:
鱼类: 无资料
甲壳类: 无资料
藻类: 无资料
残留性 / 降解性: 无资料
潜在生物累积 (BCF): 无资料
土壤中移动性
log分配系数: 1.98
土壤吸收系数 (Koc): 无资料
亨利定律 无资料
constaNT(PaM3/mol):
卡马西平 修改号码:5

模块 13. 废弃处置
如果可能,回收处理。请咨询当地管理部门。建议在可燃溶剂中溶解混合,在装有后燃和洗涤装置的化学焚烧炉中
焚烧。废弃处置时请遵守国家、地区和当地的所有法规。

模块 14. 运输信息
联合国分类: 与联合国分类标准不一致
UN编号: 未列明

模块 15. 法规信息
《危险化学品安全管理条例》(2002年1月26日国务院发布,2011年2月16日修订): 针对危险化学品的安全使用、
生产、储存、运输、装卸等方面均作了相应的规定。


模块16 - 其他信息
N/A


制备方法与用途

卡马西平简介

卡马西平为白色或类白色的结晶性粉末,属于二苯并氮杂类抗癫痫药,具有与苯妥英钠相似的抗癫痫作用。其对精神运动性发作最为有效,并对大发作、局限性发作和混合型发作也有良好的疗效。相较于苯妥英钠卡马西平在治疗外周神经痛方面更显优势,适用于三叉神经痛和舌咽神经痛等症状。此外,它还可以用于心律失常及尿崩症等的治疗。

特点

卡马西平难溶于,属于BCS II类药物,具备低溶解度、高渗透性的特点。

药理作用

卡马西平通过膜稳定作用降低神经细胞膜对Na+和Ca2+的通透性,从而减少细胞兴奋性和延长不应期;也可能增强GABA的突触传递功能。其抗惊厥机制类似于苯妥英钠,通过抑制强直后期的强化,限制致痫灶异常放电的扩散,并可抑制丘脑前腹核内的电活动。卡马西平止痛的具体机制尚不明确,但可能涉及降低中枢神经系统的突触传递。

适应症

临床中,卡马西平适用于精神运动性发作、三叉神经痛、躁狂-抑郁症、中枢性部分性尿崩症、不宁腿综合征、偏侧面肌痉挛、酒精癖的戒断症状、精神分裂症性情感性疾病以及顽固性精神分裂症等病症。

化学性质

卡马西平为白色或类白色的结晶性粉末,熔点在204-206℃(190-193℃)之间。它溶于乙醇丙酮丙二醇中而不溶于,无臭无味。

用途与生产方法 用途

卡马西平属二苯并氮杂类抗癫痫药物,其抗癫痫作用与苯妥英钠相似。对精神运动性发作最为有效,同时也适用于大发作、局限性发作和混合型发作的治疗。卡马西平在治疗外周神经痛方面优于苯妥英钠,可用于三叉神经痛和舌咽神经痛等症状。此外,它还具有抗心律失常及尿崩症等病症的作用。

生产方法
  1. 制备10,11-二氢-5H-二苯并[b,f]氮杂

  2. 卡马西平的制备

    • 使用苯为溶剂,将5H-二苯并[b,f]氮杂与异氰酸反应,再用氢氧化钠溶液调pH值至12-14后回流。将温度降至10℃以下以析出结晶,过滤、洗、干燥即得卡马西平粗品。
    • 也可通过第二条路径制备:首先在甲苯中搅拌加热溶解,进行光气化反应,减压蒸除部分甲苯,冷却析出结晶。继续回流以完成甲酰化反应,再将上述产物转入热乙醇中通,消除、胺化后即得粗品。
    • 最终粗品经乙醇重结晶、活性炭脱色处理获得成品。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    卡马西平sodium hydroxide 、 Aliquat 作用下, 以 氯仿 为溶剂, 反应 70.0h, 以62%的产率得到5-氰基-5H-二苯并[b,f]氮杂卓
    参考文献:
    名称:
    N-取代的二苯并[b,f] a庚因的光二聚反应中依赖于取代基的反应性。
    摘要:
    通过吸收和发射光谱,激光闪光光解以及通过NMR分析制备辐射研究了一系列N-取代的二苯并[b,f]氮杂苯(亚氨基苯磺酸)的光过程。在溶液中,N-氰基和N-酰基二苯并ze庚因的2pi + 2pi光二聚体在丙酮或二苯甲酮敏化的能量转移后通过三重态形成。测量了TT吸收光谱并确定了吸收系数。三重态能量转移对于不二聚的N-烷基二苯并ze庚因同样有效。讨论了后者情况下npi *字符的激发态,以合理化不同的反应性。尽管21种二苯并ze庚因衍生物的体系间交叉可忽略不计,但在浓溶液中直接激发后仍会形成N-酰基和N-氰基二苯并ze庚因的光二聚体(0。01-0.1 mol dm(-3))以及固态。整个过程中发现了对光二聚体的选择性抗构型。
    DOI:
    10.1002/chem.200305199
  • 作为产物:
    描述:
    5-氰基-5H-二苯并[b,f]氮杂卓硫酸溶剂黄146 作用下, 以 ice-water 为溶剂, 生成 卡马西平
    参考文献:
    名称:
    Process for the production of 5-cyano-and
    摘要:
    该发明涉及一种新颖且技术先进的方法,通过在强极性物质存在下,将5H-二苯并[b,f]氮杂环庚烷与卤氰试剂反应制备5-氰基-5H-二苯并[b,f]氮杂环庚烷。5-氰基-5H-二苯并[b,f]氮杂环庚烷可用作制备5-羰基-10(11)-氧代-10,11-二氢-5H-二苯并[b,f]氮杂环庚烷的起始物质,该物质已知具有抑制中枢、抗抽搐和中枢肌肉松弛活性。
    公开号:
    US04436660A1
  • 作为试剂:
    描述:
    尿素亚氨基芪硫酸卡马西平 作用下, 以 溶剂黄146 为溶剂, 反应 8.0h, 生成 Carbamazepine Sulphuric Acid
    参考文献:
    名称:
    Process for preparing carbamazepine from iminostilbene
    摘要:
    本发明公开了一种从亚胺基芪柳中制备卡马西平的方法。将亚胺基芪柳与尿素在质子化介质中反应。该方法比涉及亚胺基芪柳的现有技术方法有所改进。卡马西平是一种已知的肌肉松弛剂、抗癫痫和抗抑郁药物。
    公开号:
    US06245908B1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS<br/>[FR] CARBOXAMIDES N-HÉTÉROCYCLIQUES SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA CÉRAMIDASE ACIDE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
    申请人:BIAL BIOTECH INVEST INC
    公开号:WO2021055627A1
    公开(公告)日:2021-03-25
    The invention provides substituted N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.
    这项发明提供了替代的N-杂环羧酰胺和相关化合物,含有这些化合物的组合物,医疗工具包,以及使用这些化合物和组合物治疗患者的医疗疾病(例如癌症、溶酶体贮积症、神经退行性疾病、炎症性疾病)的方法。
  • Chemoselective Reactions of Tellurium Tetraethoxide towards Thioamides and Amides
    作者:Kazushi Omote、Yoshio Aso、Tetsuo Otsubo、Fumio Ogura
    DOI:10.1246/bcsj.67.1759
    日期:1994.6
    Tellurium tetraethoxide reacts with primary thioamides at room temperature, forming nitriles in high yields. On the other hand, the reactions with amides are largely temperature-dependent, giving predominantly esters at 80 °C and nitriles at a higher temperature. Similarly, tellurium tetraethoxide readily induces the C–N bond cleavage of ureas to give carbamates and amines.
    四乙氧基在室温下与伯酰胺反应,高效生成腈。另一方面,四乙氧基与酰胺的反应很大程度上依赖于温度,在80°C主要生成酯,而在更高温度下生成腈。同样,四乙氧基容易引发尿素中的C-N键断裂,生成氨基甲酸酯和胺。
  • [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
    申请人:GALAPAGOS NV
    公开号:WO2017012647A1
    公开(公告)日:2017-01-26
    The present invention discloses compounds according to Formula (I), wherein R1, R3, R4, R5, L1, and Cy are as defined herein. The present invention also provides compounds, methods for the production of said compounds of the invention, pharmaceutical compositions comprising the same and their use in allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 and/or interferons. The present invention also methods for the prevention and/or treatment of the aforementioned diseases by administering a compound of the invention.
    本发明公开了根据式(I)的化合物,其中R1、R3、R4、R5、L1和Cy如本文所定义。本发明还提供了该发明的化合物、制备该化合物的方法、包括相同化合物的药物组合物以及它们在过敏或炎症症状、自身免疫疾病、增殖性疾病、移植排斥、涉及软骨周转障碍的疾病、先天软骨畸形和/或与IL6和/或干扰素过度分泌相关的疾病中的使用。本发明还提供了通过给予该发明的化合物来预防和/或治疗上述疾病的方法。
  • [EN] COMPOUNDS AND THEIR USE AS BACE INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE
    申请人:ASTRAZENECA AB
    公开号:WO2016055858A1
    公开(公告)日:2016-04-14
    The present application relates to compounds of formula (I), (la), or (lb) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Αβ-related pathologies such as Down's syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
    本申请涉及式(I)、(Ia)或(Ib)的化合物及其药物组合物/制剂。本申请进一步涉及治疗或预防与Αβ相关的病理学,如唐氏综合症,β-淀粉样蛋白血管病,如但不限于脑淀粉样蛋白血管病或遗传性脑出血,与认知损害相关的疾病,如但不限于MCI(“轻度认知损害”),阿尔茨海默病,记忆丧失,与阿尔茨海默病相关的注意力缺陷症状,与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病,包括混合性血管性和退行性起源的痴呆,早老性痴呆,老年性痴呆和与帕森病相关的痴呆的方法。
  • SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS
    申请人:BLUM Andreas
    公开号:US20140135309A1
    公开(公告)日:2014-05-15
    This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R 1 and R 2 are as defined herein, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.
    这项发明涉及公式I的新型磺酰胺取代的喹唑啉生物,其中Ar、R1和R2如本文所定义,并且它们作为MNK1(MNK1a或MNK1b)和/或MNK2(MNK2a或MNK2b)激酶抑制剂的用途,含有这些化合物的药物组合物,以及将其用作治疗或改善MNK1(MNK1a或MNK1b)和/或MNK2(MNK2a或MNK2b)介导的疾病的药剂的方法。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
hnmr
mass
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台